2026-10-05
Tru Niagen keeps the top spot today, and a new independent review I came across this week only strengthens that call. ConsumerLab's ongoing NAD precursor testing continues to flag nicotinamide riboside as the better-documented option compared to NMN, which lines up exactly with why I weight regulatory history and clinical evidence so heavily in this ranking. Tru Niagen never had the FDA drug-preclusion cloud that NMN brands spent years under, and even though that cloud lifted in December 2025, it takes more than a regulatory reversal to catch up on years of accumulated human trial data. Thorne NiaCel 400 still earns its second-place spot on dose per capsule, 400mg of NR in a single capsule is a genuinely higher concentration than most competitors offer without needing multiple pills. Life Extension remains the value pick among NAD precursors specifically, consistently priced lower per effective dose while maintaining real third-party testing. On the NMN side, I am watching new research on NMNH, a reduced form of NMN that a preprint this year suggested may convert to usable NAD+ more directly, but that is one unreplicated preprint against years of NR data, not a reason to move any NMN brand up my list yet. A broader meta-analysis of 15 randomized trials this year also found NMN supplementation safe at typical doses but without clear metabolic benefit, which is a reminder that safety and efficacy are different questions. My ranking order holds steady today because none of this changes the underlying evidence gap between the NR leaders and the NMN field.
Tru Niagen's evidence lead over NMN has not closed
A regulatory reversal in December 2025 made NMN legal again, but it did not erase years of accumulated NR clinical data. ConsumerLab's ongoing reviews still favor the better-documented precursor, which is exactly why Tru Niagen holds the top spot.
Thorne NiaCel 400 still wins on dose per capsule
400mg of nicotinamide riboside in one capsule remains a genuinely higher concentration than most rivals, and that convenience factor keeps it in second place.
Life Extension remains the value pick for NAD precursors
It consistently delivers a lower price per effective dose while still backing its claims with real third-party testing, which is what value should mean in this category.
New NMNH research is interesting, not yet decisive
A preprint suggesting reduced NMN converts more directly to NAD+ is one unreplicated data point. I need more than that before moving any NMN brand up against the established NR leaders.